---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125869"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:48:34.966255+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q3 2024 revenue down 20% to $25.5M; net income falls to $2.9M from $7.5M

## Summary
- Revenue $25.5M in Q3 2024 vs $32.0M in Q3 2023, down 20% due to lower anti-fibrosis drug sales.
- Net income $2.9M in Q3 2024 vs $7.5M in Q3 2023; nine-month net income $17.3M vs $15.5M.
- Phase 3 trial for F351 in CHB liver fibrosis completed; topline data expected Q1 2025. US Phase 2 for MASH in 2025.
- Commercial launches of avatrombopag (H1 2025) and nintedanib (2025) in China expected.
- Cash and equivalents $15.9M as of Sept 30, 2024; funding runway over 12 months.

## SEC filing metadata
- accession: 0000950170-24-125869
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/0000950170-24-125869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125869
- JSON: https://secwatch.observer/filing/0000950170-24-125869.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.